نتایج جستجو برای: p53 cells

تعداد نتایج: 1407387  

Journal: :Molecular Cell 2021

Igelmann et al. report a novel metabolic cycle, which they name HTC, that converts NADH into the key antioxidant factor NADPH. The HTC is repressed by tumor suppressors p53 and RB, this determines whether oncogene-expressing cells undergo senescence (HTCoff) or malignant transformation (HTCon).

Superparamagnetic iron oxide nanoparticles (SPIONs) have made extensive advances in nanotechnology. The unique properties of these particles have expanded their application in various fields, including medicine. One of these applications is non-invasive analysis for cell tracking. However, the possibility of toxicity in cells is reported by these nanoparticles. Due to the fact that cellular dam...

2014
Lisa Lange Sarah Keppner-Witter Juline Grigat Birgit Spänkuch

PKCβ and Plk1 are fascinating targets in cancer therapy. Therefore, we combined Enzastaurin targeting PKCβ and SBE13 targeting Plk1 to test synergistic effects in cells with different p53 status. We analyzed cell proliferation and apoptosis induction, and did Western blot and FACScan analyses to examine the combined PKCβ and Plk1 inhibition. p53-wild-type cells are more resistant to the combina...

Journal: :Cancer research 2005
Mikhail V Blagosklonny Shana Trostel Ganesh Kayastha Zoya N Demidenko Lyubomir T Vassilev Larisa Y Romanova Susan Bates Tito Fojo

Mutant p53 is a cancer-specific target for pharmacologic intervention. We show that histone deacetylase inhibitors such as FR901228 and trichostatin A completely depleted mutant p53 in cancer cell lines. This depletion was preceded by induction of p53-regulated transcription. In cells with mutant p53 pretreated with histone deacetylase inhibitors, DNA damage further enhanced the p53 trans-funct...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 1995
J M Ford P C Hanawalt

We investigated whether mutations in the p53 tumor suppressor gene alter UV sensitivity and/or repair of UV-induced DNA damage in primary human skin fibroblasts from patients with Li-Fraumeni syndrome, heterozygous for mutations in one allele of the p53 gene (p53 wt/mut) and sublines expressing only mutant p53 (p53 mut). The p53 mut cells were more resistant than the p53 wt/mut cells to UV cyto...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2001
E Y Nikitina J I Clark J Van Beynen S Chada A K Virmani D P Carbone D I Gabrilovich

Accumulation of wild-type or mutant p53 protein occurs in approximately 50% of human malignancies. This overexpression may generate antigenic epitopes recognized by CTLs. Because normal cells have undetectable levels of p53, these CTLs are likely to be tumor specific. Here, for the first time, we test the hypothesis that full-length wild-type p53 protein can be used for generation of an immune ...

Journal: :The Journal of biological chemistry 2011
Sunil K Manna Charitha Gangadharan Damodar Edupalli Nune Raviprakash Thota Navneetha Sidharth Mahali Maikho Thoh

Doxorubicin is one of the most effective molecules used in the treatment of various tumors. Contradictory reports often open windows to understand the role of p53 tumor suppressor in doxorubicin-mediated cell death. In this report, we provide evidences that doxorubicin induced more cell death in p53-negative tumor cells. Several cells, having p53 basal expression, showed increase in p53 DNA bin...

2017
Bei Xie Arumugam Nagalingam Panjamurthy Kuppusamy Nethaji Muniraj Peter Langford Balázs Győrffy Neeraj K. Saxena Dipali Sharma

Functional reactivation of p53 pathway, although arduous, can potentially provide a broad-based strategy for cancer therapy owing to frequent p53 inactivation in human cancer. Using a phosphoprotein-screening array, we found that Benzyl Isothiocynate, (BITC) increases p53 phosphorylation in breast cancer cells and reveal an important role of ERK and PRAS40/MDM2 in BITC-mediated p53 activation. ...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 1998
D B Zamble T Jacks S J Lippard

Testicular cancers respond favorably to chemotherapy with the platinum-containing drug cis-diamminedichloroplatinum(II) (cisplatin). One factor that could explain the efficacy of cisplatin is the low frequency of p53 mutations observed in this tumor type. The present study examines the p53-mediated responses in murine testicular teratocarcinoma cells exposed to the drug. Cisplatin treatment of ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید